AstraZeneca, Ionis drug fails big heart disease study in major setback
BioPharma Dive
Eplontersen s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.
pharminent
July 9, 2026 (Last updated: July 9, 2026)
BioPharma Dive
Eplontersen s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.